Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
Recap by typeshit. Full story at News-Medical.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
She points to work shown at ADA 2026 and published in Nature Communications suggesting semaglutide may improve epigenetic aging markers.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
He points to a randomized clinical trial where the P11-4 peptide was tested for helping teeth rebuild mineral. Results are his to describe.
The Sunrise health expert says unregulated peptide use can put people in hospital, and in the worst cases leave them needing a new liver.
Some people on weight loss drugs are testing lower doses, hoping for fewer side effects. ThePrint reports on the trend, which these users describe themselves.
Loading…